UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Triple-negative breast cancer—current status and future directions

Annals of oncology, 2009-12, Vol.20 (12), p.1913-1927

2009

Volltextzugriff (PDF)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Volltextzugriff (PDF)

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Annals of oncology, 2023-08, Vol.34 (8), p.660-669

2023

Volltextzugriff (PDF)

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Annals of oncology, 2023-06, Vol.34 (6), p.531-542

2023

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2014-08, Vol.25 (8), p.1551-1557

2014

Volltextzugriff (PDF)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.389-399

2019

Volltextzugriff (PDF)

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Annals of oncology, 2019-05, Vol.30, p.iii67-iii67

2019

Volltextzugriff (PDF)

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Annals of oncology, 2008-05, Vol.19 (5), p.861-870

2008

Volltextzugriff (PDF)

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Volltextzugriff (PDF)

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Current medical research and opinion, 2016-07, Vol.32 (7), p.1217-1224

2016

Volltextzugriff (PDF)

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Annals of oncology, 2016-06, Vol.27 (6), p.1035-1040

2016

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2017-11, Vol.28 (11), p.2899-2899

2017

Volltextzugriff (PDF)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Volltextzugriff (PDF)

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Annals of oncology, 2017-11, Vol.28 (11), p.2899

2017

Volltextzugriff (PDF)

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of oncology, 2014-01, Vol.25 (1), p.75-80

2014

Volltextzugriff (PDF)

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Breast (Edinburgh), 2017-03, Vol.32, p.S93-S93

2017

Volltextzugriff (PDF)

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Breast (Edinburgh), 2017-03, Vol.32, p.S98-S98

2017

Volltextzugriff (PDF)

La retracción del derecho a la educación en el marco de las restauraciones conservadoras: Una mirada nuestroamericana

2021

Volltextzugriff (PDF)

La retracción del derecho a la educación en el marco de las restauraciones conservadoras

1, 2021

Volltextzugriff (PDF)

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

European journal of cancer (1990), 2015-09, Vol.51, p.S311-S311

2015

Volltextzugriff (PDF)

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

Breast (Edinburgh), 2015-03, Vol.24, p.S110-S110

2015

Volltextzugriff (PDF)

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

Breast (Edinburgh), 2015-03, Vol.24, p.S104-S105

2015

Volltextzugriff (PDF)

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

European journal of cancer (1990), 2012-03, Vol.48, p.S118-S118

2012

Volltextzugriff (PDF)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846

2017

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(129)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(21)
Female
(20)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Breast Cancer
(13)
Breast Neoplasms - Drug Therapy
(13)
Breast Neoplasms - Pathology
(13)
Middle Aged
(12)
Oncology
(12)
Adult
(10)
Hematology, Oncology And Palliative Medicine
(10)
Aged
(9)
Biological And Medical Sciences
(9)
Gynecology. Andrology. Obstetrics
(9)
Mammary Gland Diseases
(9)
Medical Sciences
(9)
Tumors
(9)
Breast Neoplasms - Mortality
(8)
Chemotherapy, Adjuvant
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Triple-negative breast cancer—current status and future directions

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

La retracción del derecho a la educación en el marco de las restauraciones conservadoras: Una mirada nuestroamericana

La retracción del derecho a la educación en el marco de las restauraciones conservadoras

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Suchergebnisse filtern